Physician profile
Karuna Narala
NPI 1457395238
$2,839.38
in general payments reported to CMS, 2019-2025
21 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.94 · 2020: $15.07 · 2021: $124 · 2022: $112 · 2023: $619 · 2024: $759 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $803.51 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $544.42 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $398.39 | 2020-2025 | |
| Glaxosmithkline, LLC. | $265.78 | 2022-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $170.82 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $146.74 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $91.24 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.79 | 2022-2025 | Jardiance |
| Amgen INC. | $56.21 | 2024-2025 | Otezla, Repatha, Repatha |
| Shield Therapeutics INC | $52.76 | 2024-2025 | |
| Astellas Pharma US INC | $52.71 | 2019-2024 | Veozah |
| Dexcom, INC. | $24.57 | 2025 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $23.97 | 2024 | |
| Merck Sharp & Dohme LLC | $23.02 | 2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $22.95 | 2023 | Freestyle Libre 2 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.66 | 2022 | |
| Exact Sciences Corporation | $16.53 | 2024 | Cologuard Collection Kit |
| Renalytix Ai, INC. | $16.33 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sumitomo Pharma America, INC. | $13.86 | 2025 | Gemtesa |
| Neurocrine Biosciences, INC. | $13.40 | 2023 | Ingrezza, Ongentys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karuna Narala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.